



Veterinary Medicine Research & Development  
Zoetis Belgium SA  
Mercuriusstraat 20, B-1930 Zaventem, Belgium



Thursday, 15 September 2022

European Medicines Agency  
Domenico Scarlattilaan 6  
1083 HS Amsterdam  
The Netherlands

**Subject: Withdrawal of Versiguard SARS CoV2 suspension for injection for mink centralised Marketing Authorization application (EMA/V/C/005988/0000)**

Dear Sir/Madam,

I would like to inform you that, at this point, Zoetis Belgium SA has taken the decision to withdraw the application for a Marketing Authorisation (MA) application for Versiguard SARS CoV2 suspension for injection for mink, which was intended to be used in mink for vaccination against SARS CoV2.

This withdrawal is based on the following reasons:

The evolving epidemiological situation with SARS CoV2 in humans and animals and the impact of this on the need for vaccination of mink.

Consideration of the investment of resources needed to address the questions raised by the CVMP during the assessment of the MA application.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s)/target species, if applicable.

We agree for this letter to be published on the EMA website.

If you should need further information or clarification, please do not hesitate to contact me.

Yours sincerely,



Zoetis Belgium S